← Leaderboards
Ralph Snodgrass
Vistagen Therapeutics, Inc.
$11,250,518
Attributed
$11,500,400
Total exposure
8
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–11$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$11,500,400 · 8
By mechanism
R44$6,295,229 · 2
U01$3,620,249 · 1
R43$1,584,922 · 5
Top collaborators
- Jong S Rim2 shared
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationEvaluationSmall Business Innovation Research GrantStem CellsBaseGene ExpressionPharmaceutical PreparationsToxic EffectPublic Health RelevanceMeetingsNeuronal InjuryDoseDrug KineticsMicroarray Technology7-Chlorokynurenic AcidCell DifferentiationNeuronsHandAdverse EffectsAnimal ModelBrainGlutamatesBlood - Brain Barrier AnatomyMaximum Tolerated Dose
Grant awards (15)
Novel Reprogrammed Cells for Differentiation into Cardiomyocytes$230,011
R43 · FY2011 · HL
Clinical Development of 4-Cl-KYN to Treat Pain$1,714,903
R44 · FY2010 · DA · contact PI
Clinical Development of 4-Cl-KYN to Treat Pain$419,898
R44 · FY2010 · DA · contact PI
Novel Reprogrammed Cells for Differentiation into Cardiomyocytes$269,754
R43 · FY2010 · HL
Clinical Development of 4-Cl-KYN to Treat Pain$2,469,281
R44 · FY2009 · DA · contact PI
Preclinical Development of 4-CI-KYN to Treat Epilepsy$1,196,369
U01 · FY2007 · NS · contact PI
Preclinical Development of 4-CI-KYN to Treat Epilepsy$1,194,505
U01 · FY2006 · NS · contact PI
Preclinical Development of 4-CI-KYN to Treat Epilepsy$1,229,375
U01 · FY2005 · NS
Preclinical Development of 4-CI-KYN to Treat Pain$196,894
R43 · FY2005 · DA
Development of 4-Chlorokynurenine to Treat Epilepsy$380,752
R43 · FY2004 · NS
Development of 4-Chlorokynurenine to Treat Epilepsy$38,000
R43 · FY2004 · NS
DEVELOPMET OF STEM CELL TECHNOLOGIES FOR TOXICOLOGY$742,682
R44 · FY2003 · GM
DEVELOPMET OF STEM CELL TECHNOLOGIES FOR TOXICOLOGY$948,465
R44 · FY2002 · GM
IN VITRO STEM CELL ASSAY FOR DRUG TOXICOLOGY ASSESSMENT$219,757
R43 · FY2001 · CA
STEM CELL TECHNOLOGIES FOR TOXICOLOGY ASSESSMENT$249,754
R43 · FY2000 · GM